YD Bio opened lower at $6.08, compared with its previous close of $6.15. In the last trading session, the stock traded between $5.11 and $6.16. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in YD Bio is now worth
$ 41.60
Resulting in a loss of
$ 58.40 (58.40%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.95 (-15.45%)
Day High
$6.16
Day Low
$5.11
Day Open
$6.08
Prev Close
$6.15
Volume
77,835
1W Return
-25.87%
1M Return
-18.81%
3M Return
91.88%
6M Return
-2.07%
1Y Return
-41.18%
Fundamentals
Market Cap ($ Mn)
368
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-282.61%
ROCE
-105.68%
EPS (TTM)
-
Investment Returns
1 Week
-25.87%
1 Month
-18.81%
3 Months
91.88%
6 Months
-2.07%
9 Months
-52.94%
Financials
Quarterly
All values in $ Mn
No data available.
Updates
1Sep
YD Bio H1FY26 Results: Revenue up 315%, net profit turns positive
Net income turned positive at $6.7 million, reversing a $1.9 million loss in H1 FY25. Revenue surged 315% YoY to $847,000, driven by a $327,000 Fetroja order. Operational loss widened 66% to $3.2 million amid rising R&D and marketing spend. Profitability driven by $9.8 million non-cash gain on warrant liabilities. Cash reserves declined 56% to $2.7 million as of June 30, 2026.
2mo ago
23Jul
YD Bio and EG BioMed conclude BIO Asia-Taiwan 2026 exhibition
YD Bio Limited and EG BioMed Co., Ltd. showcased ophthalmic and oncology innovations at BIO Asia-Taiwan 2026 in Taipei on July 19, 2026. Highlights included Exovisse™ eye care sales, upcoming Limbal Stem Cell trials, and EG BioMed’s expanded diagnostic network across 47 U.S. states. The companies also detailed U.S. market entry services and noted a pending merger agreement between YD Bio and EG BioMed.
3mo ago
2Jul
YD Bio expands US lab reach to 46 states for cancer detection
YD Bio Limited's affiliate EG BioMed US Inc. secured clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its reach to 46 U.S. states. The licenses, issued in May and June 2026, cover clinical genetics, chemistry, and hematology. This supports YD Bio's early cancer detection operations and blood-based testing services.
